Dear Secretary Clinton: We write to you in the sincere hope that we can work together to transform the pain caused by your March 11th mischaracterization of the Reagans’ role in the AIDS crisis into an urgently needed public discussion of a plan to end the United States HIV epidemic by the year 2025.
I would like to offer comments to correct the record on statements given by Senator Bill Cassidy (R-LA) at the October 7, 2015, hearing on the National Institutes of Health fiscal year 2016 budget. Several of his comments to the committee and NIH Director Francis Collins were incorrect or misleading. If his erroneous statements about AIDS research funding at the NIH are mistaken for fact, we will set a dangerous course for current and future research being conducted at the agency and undermine the prioritization process under way at the Office of AIDS Research (OAR).
Letter signed by a number of organizations and individuals urging Gilead to consider drug pricing that addresses the need for cost-contained HIV care delivery in the U.S.
TAG, CRAG, and other civil society organizations sent this letter to The Union, asking them, as producers of the world’s largest TB conference and publisher of the field’s flagship journal to lead by example...
150 organizations called on six pharmaceutical companies to continue funding the vital D:A:D study. 150 HIV Organizations Urge Continuation of D:A:D Study
We write as professionals, activists, and public health researchers who have worked to combat AIDS and other infectious diseases in the United States and around the world for over three decades.
Letter from TAG and others asking for withdrawal of mandatory quarantine requirement for entering the US through Newark and JFK airports who have had direct contact with individuals with Ebola Virus Disease in Guinea, Liberia, and Sierra Leone.
Letter from TAG and other advocates expressing concerns about proposed Medicaid criteria that will limit access to sofosbuvir and other lifesaving hepatitis C medications.
Letter asking to speak to key staff at Novartis to discuss its support of the clinical research required to more fully understand the efficacy of Menveo in adolescents and adults living with HIV.
Follow-up to January 14, 2014 letter regarding the development of a plan to end AIDS in New York State.